Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Surface Oncology Inc (SURF)

Surface Oncology Inc (SURF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 262,969
  • Shares Outstanding, K 46,135
  • Annual Sales, $ 126,160 K
  • Annual Income, $ 59,340 K
  • 60-Month Beta 1.59
  • Price/Sales 2.07
  • Price/Cash Flow 3.78
  • Price/Book 1.96
Trade SURF with:

Options Overview Details

View History
  • Implied Volatility 90.62%
  • Historical Volatility 36.05%
  • IV Percentile 19%
  • IV Rank 34.14%
  • IV High 155.52% on 03/05/21
  • IV Low 56.97% on 11/17/21
  • Put/Call Vol Ratio 0.29
  • Today's Volume 844
  • Volume Avg (30-Day) 258
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 5,426
  • Open Int (30-Day) 6,365

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate 0.17
  • Low Estimate -0.46
  • Prior Year 1.56
  • Growth Rate Est. (year over year) -109.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.41 +5.91%
on 11/26/21
7.97 -28.11%
on 11/04/21
-1.69 (-22.78%)
since 10/29/21
3-Month
5.41 +5.91%
on 11/26/21
8.38 -31.62%
on 09/20/21
-0.52 (-8.32%)
since 08/27/21
52-Week
4.95 +15.76%
on 08/04/21
14.40 -60.21%
on 01/21/21
-2.13 (-27.10%)
since 11/27/20

Most Recent Stories

More News
Preclinical Data Supporting Therapeutic Potential of Surface Oncology’s Lead Clinical Programs, SRF617 and SRF388, Presented at the Society for Immunotherapy of Cancer 2021 Annual Meeting

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation...

SURF : 5.73 (+0.53%)
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2021

Company to initiate randomized Phase 2 clinical study evaluating SRF388 in combination with Roche’s atezolizumab and bevacizumab, in patients with...

SURF : 5.73 (+0.53%)
Surface Oncology to Present Preclinical Data for Lead Clinical Programs at the Society for Immunotherapy of Cancer 2021 Annual Meeting

CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation...

SURF : 5.73 (+0.53%)
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026

Palm Beach, FL – September 20, 2021 – FinancialNewsMedia.com News Commentary – Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements...

ONCY : 1.7200 (-4.97%)
ONC.TO : 2.21 (-0.90%)
CRVS : 3.45 (+1.17%)
IPHA : 4.99 (+3.96%)
SURF : 5.73 (+0.53%)
CLVS : 3.09 (-3.44%)
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2021

SRF388, a First-in-Class Anti-IL-27 Antibody, Demonstrates Monotherapy Activity in Ongoing Phase 1 Study; Enrollment Continues for Phase 2 Monotherapy Expansion and Combination Cohorts

SURF : 5.73 (+0.53%)
Surface Oncology Appoints Denice Torres to Board of Directors

Brings 25 years of strategic leadership experience across healthcare

SURF : 5.73 (+0.53%)
SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monotherapy Activity in Data Presented at American Society of Clinical Oncology Annual Meeting

Preliminary Data for SRF617 Show Good Tolerability and Promise in Combination Approaches

SURF : 5.73 (+0.53%)
Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, as Part of a Novel Combination in Patients with Advanced Treatment-naïve Hepatocellular Carcinoma

CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment,...

SURF : 5.73 (+0.53%)
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021

CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment,...

SURF : 5.73 (+0.53%)
Surface Oncology to Present Clinical Updates for SRF388 and SRF617

SRF388 Phase 1 Update to be Presented at American Society for Clinical Oncology Annual Meeting

SURF : 5.73 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Surface Oncology, Inc. is a clinical-stage immuno-oncology company. It develops therapies for the treatment of cancer. The company's product pipeline includes CD47, CD73, SRF231, SRF373, SRF617, SRF388 and SRF231 which are in clinical stage. Surface Oncology is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 5.99
2nd Resistance Point 5.90
1st Resistance Point 5.82
Last Price 5.73
1st Support Level 5.65
2nd Support Level 5.56
3rd Support Level 5.48

See More

52-Week High 14.40
Fibonacci 61.8% 10.79
Fibonacci 50% 9.67
Fibonacci 38.2% 8.56
Last Price 5.73
52-Week Low 4.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar